Keyphrases
Acceptable Safety
6%
Advanced Basal Cell Carcinoma
73%
Advanced Cutaneous Squamous Cell Carcinoma
34%
Advanced or Metastatic
9%
Adverse Events
6%
Antitumor Activity
8%
Basal Cell Carcinoma
32%
Blinded Independent Central Review
10%
Cemiplimab
39%
Complete Response
8%
Confidence Interval
6%
Cutaneous Squamous Cell Carcinoma (cSCC)
33%
Duration of Response
12%
Dysgeusia
5%
Head and Neck Cutaneous Squamous Cell Carcinoma
6%
Head-and-neck
8%
Hedgehog Inhibitor
36%
Hedgehog Signaling Pathway
5%
Inhibitor Therapy
5%
LDE225
5%
Locally Advanced
22%
Locally Advanced Cutaneous Squamous Cell Carcinoma
9%
Long-term Efficacy
16%
Long-term Safety
12%
Metastatic Basal Cell Carcinoma
23%
Metastatic Cancer
5%
Metastatic Cutaneous Squamous Cell Carcinoma
10%
Mohs Micrographic Surgery
12%
Muscle Spasm
5%
Non-melanoma Skin Cancer
10%
Objective Response Rate
23%
Partial Response
6%
PD-1 Inhibitor
6%
Phase II Study
9%
Response Rate
5%
Safety Profile
6%
Sonidegib
38%
Squamous Cell Carcinoma (SqCC)
8%
Squamous Cell Carcinoma of Head
8%
Surgical Excision
5%
Systemic Therapy
7%
Treatment Options
7%
Treatment-related Adverse Events
5%
Vismodegib
29%
Medicine and Dentistry
Actinic Keratosis
5%
Adverse Effect
5%
Arm
9%
Basal-Cell Carcinoma
62%
Biopsy Technique
5%
Cancer
9%
Cemiplimab
17%
Clinical Trial
5%
Dermatology
5%
Dermatosis
6%
Diagnosis
5%
Disease Specific Survival
6%
Diseases
27%
Hedgehog Signaling
19%
Immunotherapy
10%
Malignant Neoplasm
18%
Melanoma
11%
Metastatic Carcinoma
13%
Mohs Surgery
12%
Neck
16%
Neoplasm
24%
Non Melanoma Skin Cancer
22%
Oncology
5%
Photograph
7%
Radiation Therapy
5%
Skin Cancer
7%
Skin Carcinoma
64%
Sonidegib
26%
Squamous Cell Carcinoma
8%
Systemic Therapy
9%
Vismodegib
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
12%
Antitumor Activity
6%
Basal Cell Carcinoma
100%
Cemiplimab
46%
Clinical Trial
6%
Diseases
22%
Head and Neck Squamous Cell Carcinoma
5%
Hedgehog
46%
Immunotherapy
13%
Malignant Neoplasm
16%
Melanoma
5%
Neoplasm
23%
Non Melanoma Skin Cancer
9%
Overall Survival
7%
Pharmacokinetic
8%
Skin Carcinoma
53%
Sonidegib
42%
Systemic Treatment
5%
Vismodegib
36%